The Effect of Intravitreal Injection of Anti-VEGF on Perfusion Indices in Eyes with Diabetic Macular Edema Measured by Optical Coherence Tomography Angiography, ABD EL RAHMAN G. SALMAN, MOUAMEN M. MOSTAFA, HATEM F. ABD ELFATAH and MOSTAFA G. MANSOUR
Abstract
Background: Anti-VEGF agents interfere with receptor binding, thus inhibiting VEGF’s signal, which results in inhi-bition of abnormal blood vessel formation and decreased vas-cular permeability. Anti-VEGFs have significant roles in the treatment of many retinal diseases as age related macular de-generation, myopic choroidal neovascularization, proliferative diabetic retinopathy, diabetic macular edema and retinal vein occlusion. Aim of Study: To evaluate changes in macular vessel den-sity following first dose of intravitreal anti-VEGF injection of ranibizumab (Lucentis®) in patients with diabetic macular ede-ma (DME). Patients and Methods: This prospective study included 44 eyes of 44 DME patients indicated for IVI of Ranibizumab, with mean age 50.98±6.27 years, ranging from 41.0 years to 60.0 years. The majority of them were males (68.2%). Results: Vessel density (central subfield) at baseline (20.29 ±1.89) didn’t show statistically significant difference than that at one month (20.09±2.4) but showed a highly significant differ-ence at two months (19.73±2.49) after IVI. Vessel density (av-erage of the four parafoveal sub fields) at baseline (44.98±2.6) didn’t show statistically significant difference than that at one month (44.8±2.21) but showed a highly significant difference at two months (44.14±2.2) after IVI. Conclusion: A single IV injection of Ranibizumab in eyes with DME showed non significant vascular density changes after one month of injection in both central and paraoveal sub-fileds but a statistically significant decrease in vascular density 2 months after injection.